FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
NEWTOWN, Pa., May 01, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced one oral and one poster presentation at the 14th International Symposium on Myelodysplastic Syndromes taking place May 3-6, 2017 at the Palacios de Congresos de Valencia in Valencia, Spain. These presentations will be made by the Company’s collaborators from the Mount Sinai School of Medicine and the Cleveland Clinic.
Abstract Details:
Poster Presentation:
Date: May 4th through May 6th
Time: 8:00 am
Location: Poster Presentation Section
Presenter: Dr. Aziz Nazha - Cleveland Clinic, Cleveland, Ohio
A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial
Oral Presentation:
Date: Saturday May 6th
Time: 8:30 am-10 am
Location: Auditorium 1
Presenter: Dr. Shyamala Navada - Mount Sinai School of Medicine, NYC
Combination of Oral Rigosertib and Injectable Azacitidine In Patients with Myelodysplastic Syndromes (MDS)
Additional details and content from these presentations will be available on the Company’s website on the day of the presentations.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with Onconova’s lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics [email protected] / (212) 750-5800
